Chronic Myelogenous Leukemia with Multiple BCR::ABL1 Transcripts: A Case Report
Author Information
Author(s): Xu Yang, Fan Yuying, Liu Sijin, Chang Jianmei, Guo Caifeng, Chen Lanhui, Guo Wenzheng, Dang Jinwen, Wang Hongwei, Tan Yanhong
Primary Institution: Institute of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China
Hypothesis
What is the drug response of chronic myelogenous leukemia (CML) with variant BCR::ABL1 transcripts?
Conclusion
The patient with chronic myelogenous leukemia expressing multiple BCR::ABL1 transcripts showed a favorable response to treatment with flumatinib.
Supporting Evidence
- The patient expressed four BCR::ABL1 transcripts, including two variant and two classical types.
- Monitoring showed a decreasing trend in the expression of all four transcripts over time with treatment.
- The V-e13a2 transcript became undetectable after 9 months of treatment.
Takeaway
This study is about a 66-year-old woman with a rare type of leukemia that has different genetic changes. She was treated with a special medicine and got better.
Methodology
The patient was treated with flumatinib and monitored for 14 months using RT-qPCR to assess the response of various BCR::ABL1 transcripts.
Limitations
The study is based on a single case report, limiting the generalizability of the findings.
Participant Demographics
A 66-year-old Chinese female patient.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website